RasGRP1 is a causal factor in the development of l-DOPA–induced dyskinesia in Parkinson’s disease

The therapeutic effects of l-3,4-dihydroxyphenylalanine (l-DOPA) in patients with Parkinson’s disease (PD) severely diminishes with the onset of abnormal involuntary movement, l-DOPA–induced dyskinesia (LID). However, the molecular mechanisms that promote LID remain unclear. Here, we demonstrated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Eshraghi, Mehdi, Ramírez-Jarquín, Uri Nimrod, Shahani, Neelam, Nuzzo, Tommaso, De Rosa, Arianna, Swarnkar, Supriya, Galli, Nicole, Rivera, Oscar, Tsaprailis, George, Scharager-Tapia, Catherina, Crynen, Gogce, Li, Qin, Thiolat, Marie-Laure, Bezard, Erwan, Usiello, Alessandro, Subramaniam, Srinivasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195186/
https://www.ncbi.nlm.nih.gov/pubmed/32426479
http://dx.doi.org/10.1126/sciadv.aaz7001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195186/
https://www.ncbi.nlm.nih.gov/pubmed/32426479
http://dx.doi.org/10.1126/sciadv.aaz7001

Ejemplares similares